Skip to main content
OpenTrials
Completed

NCT Number: NCT02757313

Neuroscience of Marijuana Impaired Driving

Marijuana is one of the most widely used substances. However, marijuana intoxication is not fully understood in relation to driving. This study will help the investigators learn more about the potential impairments related to marijuana intoxicated driving. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure intoxication and impairment. This study will also assess levels of marijuana in blood and saliva samples. This study takes place in Hartford, Connecticut.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Marijuana Impairment Chemically-Induced Disorders Marijuana Abuse Mental Disorders Substance-Related Disorders

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Olin Neuropsychiatry Research Center

Hartford, Connecticut, 06106, United States

About this study

Cannabis is a commonly abused drug whose use cuts across social class, is linked to cognitive impairment, and may be a major contributor to intoxication-related accidents - either alone or with alcohol. However, cannabis intoxication is little studied in relation to driving compared to alcohol. Not only does the current NHTSA Strategic Plan for Behavioral Research prioritize understanding how drugs other than alcohol contribute to traffic crashes, it has recently become more pressing to understand the effects of cannabis because of increasing rates of legalized medical and/or recreational use, that will likely result in more cannabis intoxicated drivers. Social and legal policy will be unable to effectively address the many concerns about driving safety raised by more frequent and widespread use of cannabis without new research to better determine the parameters within which cannabis use does, or does not, increase automobile accident risk. The purpose of this study is to better describe specific, driving-related cognitive impairments caused by acute cannabis intoxication, their persistence over time, underlying functional brain anatomy, and relationship to performance on a state-of the art validated simulated driving task in which the investigators have prior experience. In a randomized, counterbalanced, double-blinded fashion, the investigators will administer two cannabis doses and placebo of smoked cannabis (paced inhalation using a vaporizer) to 48 regular cannabis users and 48 occasional cannabis users on 3 separate occasions. Following cannabis dosing cognitive and driving impairment will be assessed longitudinally for several hours using a combination of fMRI and neuropsychological tests, to clarify relationships between subjective and objective measures of intoxication and of impairment, that include expert assessment of THC and its metabolite levels in blood and saliva. This study takes place in Hartford, Connecticut.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must have a current driver's license
  • Have used marijuana before
  • Right handed

Exclusion criteria

  • Females who are pregnant or breast feeding
  • Unable or unsafe to have an MRI
  • Any serious medical, or neurological disorder
  • Any psychiatric disorder
  • No major head traumas

Treatment and study plan

Low Dose THC Marijuana

Drug

Other names: THC, cannabis

High Dose THC Marijuana

Drug

Other names: THC, cannabis

Placebo Marijuana

Drug

Other names: THC, cannabis

Primary outcomes

  1. Change in performance on fMRI simulated driving Gap Acceptance Task

    Time frame: Post drug administration at: 30 min, 3 hours and 5.25 hours

    The Gap Acceptance Task measures strategic control of the vehicle. Strategic control of the vehicle is measured by size of headway gaps that the participant chooses in pulling out into a stream of traffic.

  2. Change in performance on fMRI simulated driving Road Tracking Task.

    Time frame: Post drug administration at: 30 min, 3 hours and 5.25 hours

    The Road Tracking Task measures operational control of the vehicle. Operational control is measured by standard deviation of lane position from the center point of the lane.

  3. Change in performance on fMRI simulated driving Car Following Task.

    Time frame: Post drug administration at: 30 min, 3 hours and 5.25 hours

    The Car Following Task measures tactical control of the vehicle. Tactical control of the vehicle is measured by following distance from a lead vehicle.

  4. Change in concentration of THC/metabolites in oral fluid tested using Draeger Drug Detection Kits

    Time frame: Baseline and post drug administration at: 5 min, 20 min, 1 hr 10 min, 1 hr 45 min, 2 hrs 30 min, 4 hrs, and 6 hrs 30 min,

    Saliva samples will be taken at 8 total time points throughout the day using the Draeger Drug Detection kits to assess for changes in concentration of THC and its metabolites.

  5. Change in concentration of THC/metabolites in oral fluid tested using Quantisal Oral Fluid Collection devices.

    Time frame: Baseline and post drug administration at: 5 min, 20 min, 1 hr 10 min, 1 hr 45 min, 2 hrs 30 min, 4 hrs, and 6 hrs 30 min,

    Saliva samples will be taken at 8 total time points throughout the day using the Quantisal Oral Fluid Collection devices to assess for changes in concentration of THC and its metabolites.

  6. Change in concentration of THC/metabolites in blood samples.

    Time frame: Baseline and post drug administration at: 5 min, 20 min, 1 hr 10 min, 1 hr 45 min, 2 hrs 30 min, 4 hrs, and 6 hrs 30 min,

    Blood samples will be taken at 8 total time points throughout the day to assess for changes in concentration of THC and its metabolites.

  7. Marijuana performance changes on the Critical Tracking Task.

    Time frame: Post drug administration at two of the following time points (which varies dependent on the visit day): 2 hours; 4.25 hours; 6.5 hours

    The Critical Tracking Task assesses visuomotor tracking, it will be administered prior to dosing and at various time points after dosing.

  8. Marijuana performance changes on the Tower of London task.

    Time frame: Post drug administration at two of the following time points (which varies dependent on the visit day): 2 hours; 4.25 hours; 6.5 hours

    The Tower of London is a task that assesses executive functioning, it will be administered prior to dosing and at various time points after dosing.

  9. Marijuana performance changes on the Cogstate 1-back/2-back task.

    Time frame: Post drug administration at two of the following time points (which varies dependent on the visit day): 2 hours; 4.25 hours; 6.5 hours

    The Cogstate 1-back/2-back task assesses working memory, it will be administered prior to dosing and at various time points after dosing.

  10. Marijuana performance changes on the Cogstate Detection Task.

    Time frame: Post drug administration at two of the following time points (which varies dependent on the visit day): 2 hours; 4.25 hours; 6.5 hours

    The Cogstate Detection Task assesses processing speed, it will be administered prior to dosing and at various time points after dosing.

  11. Marijuana performance changes on the Cogstate Set Shifting Task.

    Time frame: Post drug administration at two of the following time points (which varies dependent on the visit day): 2 hours; 4.25 hours; 6.5 hours

    The Cogstate Set Shifting Task assesses executive functioning, it will be administered prior to dosing and at various time points after dosing.

Secondary outcomes

  1. Change in performance on fMRI Set-Shifting paradigm.

    Time frame: Post drug administration at: 1.25 hours, 3.5 hours and 6 hours

    The set shifting paradigm measures attentional and executive domains.

  2. Change in performance on fMRI Time Estimation paradigm.

    Time frame: Post drug administration at: 1.25 hours, 3.5 hours and 6 hours

    The time estimation paradigm measures misjudgment of time intervals based on participant responses indicating whether one time interval was the same, longer or shorter than the previous time interval.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • Hartford Hospital
  • Maastricht University
  • Montana State University
  • National Institute on Drug Abuse (NIDA)
  • The Mind Research Network

Registry information

Acronym: MJDriving

Important dates

Study start
2016
Primary completion
2021
Study completion
2021
First posted
May 2, 2016
Registry last updated
Jul 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.